PMC9302584_01
Treatment course with corresponding computed tomography (CT) scans. This figure shows the timeline of progression after 43 months under the treatment with only icotinib; the patient achieved a satisfactory exceptional response by treatment with osimertinib plus ensartinib.
fmed-09-906364-g0001.jpg
PMC9302584_01_fmed-09-906364-g0001.jpg
F1
A 64-year-old man with no smoking history and no history of cancer presented to our hospital in September 2016 with a primary tumor (1.5 x 1.5 cm) in his upper left lung (Figure 1). The timeline of the disease progression is shown in Figure 1. After 15 months of icotinib treatment, a CT scan of the patient revealed progressive disease (PD) (Figure 1). The patient experienced serious pleural effusion on the left side and significantly enlarged para-aortic lymph nodes (6, 30.3 mm) (Figure 1). Regular follow-up chest CT indicated that the lesion was stable through March 2022 (Figure 1).
The pathological diagnosis of specimens was lung adenocarcinoma. H and E staining and immunohistochemistry staining of surgical, pleural effusion, and biopsy specimens.
fmed-09-906364-g0002.jpg
PMC9302584_01_fmed-09-906364-g0002.jpg
F2
The immunohistochemical staining is shown in Figure 2.